DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Tanespimycin is an investigational drug.
There have been 33 clinical trials for Tanespimycin. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2008.
The most common disease conditions in clinical trials are Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, and Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Bristol-Myers Squibb, and Memorial Sloan Kettering Cancer Center.
Recent Clinical Trials for Tanespimycin
|Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer||National Cancer Institute (NCI)||Phase 2|
|A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse||Bristol-Myers Squibb||Phase 3|
|Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer||National Cancer Institute (NCI)||Phase 2|